GlassScriptPhysician profile
Hera Rahman
NPI 1821611609
$8,063.01
in general payments reported to CMS, 2019-2025
42 companies · $3,686 in 2025
The $3,686 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,214 · 2024: $3,163 · 2025: $3,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,026 · Education: $36.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,026.04 |
| Education | $36.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,447.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $1,037.04 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $857.10 | 2023-2025 | Korlym |
| Novo Nordisk INC | $450.08 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $377.33 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $329.36 | 2024-2025 | |
| Mannkind Corporation | $307.21 | 2023-2025 | Afrezza |
| Alexion Pharmaceuticals, INC. | $297.19 | 2023-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $243.03 | 2023-2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $233.58 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $232.32 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $169.25 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $161.73 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $156.92 | 2024-2025 | Unithroid |
| Amgen INC. | $149.95 | 2023-2025 | Evenity, Prolia, Prolia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.29 | 2024-2025 | Jardiance, Synjardy |
| Radius Health, INC. | $130.86 | 2024-2025 | Tymlos |
| Esperion Therapeutics, INC. | $117.63 | 2023-2025 | Nexletol |
| Madrigal Pharmaceuticals | $112.16 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $100.34 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $98.40 | 2023-2024 | Crysvita |
| Ibsa Pharma INC. | $90.04 | 2024-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $82.58 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $79.82 | 2024-2025 | |
| Antares Pharma, INC. | $72.58 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $68.04 | 2024-2025 | Veozah |
| Verity Pharmaceuticals INC. | $65.28 | 2025 | Tlando |
| Abbott Laboratories | $54.33 | 2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $47.46 | 2024-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $46.26 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Halozyme INC | $43.29 | 2023 | |
| Cequr Corporation | $39.16 | 2023-2024 | Cequr Simplicity |
| Acella Pharmaceuticals, LLC | $34.32 | 2023-2025 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $31.01 | 2025 | Shingrix, Arexvy |
| Viiv Healthcare Company | $27.73 | 2025 | Apretude |
| Medtronic, INC. | $24.44 | 2025 | Intellis Adaptivestim |
| Chiesi USA, INC. | $21.68 | 2025 | Mycapssa |
| Vivus LLC | $21.03 | 2025 | Qsymia |
| Amryt Pharma Holdings LTD | $17.61 | 2023 | Mycapssa |
| Otsuka America Pharmaceutical, INC. | $14.42 | 2025 | Rexulti |
| Ionis Pharmaceuticals, INC. | $13.59 | 2025 | Tryngolza |
| Theracosbio, LLC | $11.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hera Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.